Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T13148 | CHK-IN-1 | 1278405-51-8 | 100% |
|
CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity. | ||||
TN1458 | Buddlejasaponin IV | 139523-30-1 | 98% |
|
Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-ka... | ||||
T17223 | VER-00158411 | 1174664-88-0 | 98% |
|
VER-00158411 is a checkpoint kinase 1 and CHK2 inhibitor (IC50: 4.4 nM and 4.5 nM, respectively). | ||||
T10790 | CHK1-IN-2 | 912367-45-4 | 98% |
|
CHK1-IN-2 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 6 nM). | ||||
T16848 | SB-218078 | 135897-06-2 | 98% |
|
SB-218078 is less potently inhibits Cdc2 (IC50: 250 nM) and PKC (IC50: 1000 nM). SB-218078 is a potent, ATP-competitive, and cell-permeable checkpoint kinase 1 i... | ||||
T10793 | CHK1 inhibitor | 2097938-64-0 | 98% |
|
CHK1 inhibitor (GDC-0575 analog) is a CHK1 inhibitor. | ||||
T10718 | CCT241533 | 1262849-73-9 | 98% |
|
CCT241533 is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM). | ||||
T14904 | CCT244747 | 1404095-34-6 | 98% |
|
CCT244747 is a CHK1 inhibitor (IC50: 7.7 nM) and also abrogates G2 checkpoint (IC50: 29 nM). | ||||
T10792 | CHK1-IN-4 | 2120398-41-4 | 98% |
|
CHK1-IN-4 is a potent inhibitor of checkpoint kinase 1 (chk1) and potently inhibits chk1 phosphorylation in the tumor cells with anti-tumor activity. | ||||
T76691 | Monalizumab | 1228763-95-8 | SDS-PAGE:95% SEC-HPLC:95% |
Monalizumab
|
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NK... | ||||
T11960 | MBM-55 | 2083622-09-5 | 99.98% |
|
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing... | ||||
T9252 | LY2880070 | 1375637-35-6 | 99.95% |
|
LY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy. | ||||
T3700 | SCH900776 (S-isomer) | 891494-64-7 | 99.95% |
|
SCH900776 S-isomer (MK-8776 S-isomer) is an effective, specific and orally bioavailable inhibitor of checkpoint kinase Chk1 (IC50: 3 nM). It also inhibitors Chk2... | ||||
T83321 | 4-Demethyldeoxypodophyllotoxin | 3590-93-0 | 99.89% |
|
4-Demethyldeoxypodophyllotoxin, an aryl tetrahydronaphthalenyl lignan analog from the roots of Podophyllum peltatum, has anticancer activity and modulates the Ch... | ||||
T2485 | Baricitinib | 1187594-09-7 | 99.79% |
|
Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineopla... | ||||
T7080 | CCT245737 | 1489389-18-5 | 99.69% |
|
CCT245737 (SRA737) is an orally active and selective Chk1 inhibitor (IC50: 1.3 nM); CCT245737 shows much less activity against Chk2 (IC50: 2440 nM). | ||||
T10406 | Tuvusertib | 1613200-51-3 | 99.66% |
|
Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 µΜ) with selective and potentially antitumor activ... | ||||
T6931 | PD0166285 | 185039-89-8 | 99.59% |
|
PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator. | ||||
T6084 | Rabusertib | 911222-45-2 | 99.40% |
|
Rabusertib (IC-83) is an inhibitor of the cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiating activity. Rabusertib has been used in trials stu... | ||||
T1837 | BX-912 | 702674-56-4 | 99.34% |
|
BX-912 is a specific inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1, IC50: 12 nM). The selectivity of BX-912 is more 10 fold than C-Kit, EGFR, PKA, PKC... |